News Novo's oral GLP-1 is first to claim heart health label Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction.
News Novo reels in Replicate for new cardiometabolic drugs Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes.
News Lilly pauses Mounjaro orders in UK ahead of price hike Lilly has paused shipments of weight loss therapy Mounjaro to the UK to prevent stockpiling ahead of a price rise, but patients report shortages.
News Diabetics on Lilly's orforglipron shed 10.5% of their weight Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.
News Twin Health raises $53m, as study backs 'digital twin' AI Twin Health has raised $53m to fund further rollout of its digital twin AI, shown to improve glucose control in diabetics in a just-published study.
News New NHS diabetes strategy could raise GLP-1 drug use New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.